復星醫藥：藥品FXS0683片獲臨床試驗批准

每日經濟新聞

03/13

每經AI快訊，復星醫藥(600196)3月13日公告，近日，公司控股子公司上海復星醫藥產業發展有限公司收到國家藥品監督管理局關於同意FXS0683片用於血液系統惡性腫瘤開展臨床試驗的批准。復星醫藥產業擬於條件具備後於中國境內開展FXS0683的I期臨床研究。FXS0683為本集團（即本公司及控股子公司/單位）自主研發的口服小分子創新藥，為強效及高選擇性的新一代Bcl-2抑制劑，擬用於治療血液系統...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hant/news/2619419839"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2619419839\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2619419839?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-13 17:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619419839","market":"us","top_or_hot":-1,"title":"復星醫藥：藥品FXS0683片獲臨床試驗批准","media":"每日經濟新聞","content":"<div>\n<p>每經AI快訊，復星醫藥(600196)3月13日公告，近日，公司控股子公司上海復星醫藥產業發展有限公司收到國家藥品監督管理局關於同意FXS0683片用於血液系統惡性腫瘤開展臨床試驗的批准。復星醫藥產業擬於條件具備後於中國境內開展FXS0683的I期臨床研究。FXS0683為本集團（即本公司及控股子公司/單位）自主研發的口服小分子創新藥，為強效及高選擇性的新一代Bcl-2抑制劑，擬用於治療血液系統...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202603133671586823.html\">網頁鏈接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>復星醫藥：藥品FXS0683片獲臨床試驗批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n復星醫藥：藥品FXS0683片獲臨床試驗批准\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">每日經濟新聞</strong><span class=\"h-time small\">2026-03-13 17:27</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>每經AI快訊，復星醫藥(600196)3月13日公告，近日，公司控股子公司上海復星醫藥產業發展有限公司收到國家藥品監督管理局關於同意FXS0683片用於血液系統惡性腫瘤開展臨床試驗的批准。復星醫藥產業擬於條件具備後於中國境內開展FXS0683的I期臨床研究。FXS0683為本集團（即本公司及控股子公司/單位）自主研發的口服小分子創新藥，為強效及高選擇性的新一代Bcl-2抑制劑，擬用於治療血液系統...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202603133671586823.html\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://finance.eastmoney.com/a/202603133671586823.html\">每日經濟新聞</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"復星醫藥","start_time":0,"source_url":"http://finance.eastmoney.com/a/202603133671586823.html","article_id":"2619419839","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603133671586823.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619419839","pubTimestamp":1773394042,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"每經AI快訊，復星醫藥(600196)3月13日公告，近日，公司控股子公司上海復星醫藥產業發展有限公司收到國家藥品監督管理局關於同意FXS0683片用於血液系統惡性腫瘤開展臨床試驗的批准。復星醫藥產業擬於條件具備後於中國境內開展FXS0683的I期臨床研究。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","02196":"复星医药","BK0060":"抗癌","BK0028":"国家队","BK0239":"医药制造","BK0183":"MSCI概念","BK1191":"制药","BK1515":"抗疫概念","BK0096":"民营医院","BK0188":"融资融券","BK1593":"医美概念股","BK0012":"证金概念","BK0196":"行业龙头","BK0175":"白马股","BK0187":"一线龙头"},"translate_title":"Fosun Pharma: Drug FXS0683 Tablets Approved for Clinical Trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1.5,"02196":1.5},"content_text":"每經AI快訊，復星醫藥(600196)3月13日公告，近日，公司控股子公司上海復星醫藥產業發展有限公司收到國家藥品監督管理局關於同意FXS0683片用於血液系統惡性腫瘤開展臨床試驗的批准。復星醫藥產業擬於條件具備後於中國境內開展FXS0683的I期臨床研究。FXS0683為本集團（即本公司及控股子公司/單位）自主研發的口服小分子創新藥，為強效及高選擇性的新一代Bcl-2抑制劑，擬用於治療血液系統惡性腫瘤。（文章來源：每日經濟新聞）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}